The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Circulating tumor cells as prognostic and molecular biomarkers in multiple myeloma
Luca Bertamini, MD, Erasmus MC, Rotterdam, Netherlands, discusses the potential value of circulating tumor cells (CTCs) for risk stratification and molecular profiling in multiple myeloma. He highlights how CTC burden is associated with outcomes and how CTCs can provide information on tumor biology and high-risk genetic features, supporting their potential role as a prognostic and liquid biopsy tool. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
